BioSpace News Archive

Avalo Therapeutics, Inc., a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced that members of its senior management team will present at two upcoming conferences.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at two upcoming virtual conferences:

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the oral formulation of XENLETA® (lefamulin) is now available in a 10-count oral pack in the U.S. through major specialty distributors.

Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 8:00 a.m. E.T.

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:

Ginkgo Bioworks, the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits service.

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented two posters at the Society for Neuroscience’s (SfN) 50th Annual Meeting (“Neuroscience 2021") held virtually November 8-11.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a virtual fireside chat at The Jefferies London Healthcare Conference.

4D pharma plc today announces that 4D pharma management will participate in the Jefferies London Virtual Healthcare Conference, being held November 18-19, 2021.

Gemini Therapeutics, Inc., a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration, announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November: